Not for use in diagnostic procedures (except as specifically noted). Karen Birmingham, PhD SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)-- “We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. Perhaps with that misadventure in mind, not to mention Grail's apparently high price tag, traders sent Illumina stock down by nearly 8.5% on Wednesday -- … lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. Illumina will offer GRAIL stockholders the option to receive additional cash and/or stock consideration, in an amount to be determined prior to closing, in lieu of the contingent value rights. This includes $3.5 billion in cash and $4.5 … Prior to the IPO, Illumina held 14.6% of shares, making it the largest single shareholder. This will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. The majority of what he knows about stocks he learned right here at the Motley Fool. This includes $3.5 billion in cash and $4.5 billion … GRAIL $ $ $ $ 2020. The agreement has been approved by the Boards of Directors of Illumina and GRAIL. Illumina is rumoured to be in talks with oncology testing company Grail over a potential $8bn bid. Illumina's news of its $8 billion deal to acquire Grail, a healthcare company focused on cancer detection, has ILMN stock down on Monday. The deal confirmed … Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. That’s more than double Grail’s last known valuation. In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1.0 billion bridge facility with Goldman Sachs Bank USA. Shares of Illumina (NASDAQ:ILMN) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion. (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. At closing, Illumina said, it and other GRAIL shareholders will receive $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a “collar” designed to ensure that GRAIL stockholders excluding Illumina receive Illumina … Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. Illumina will buy the remaining stake in Jeff Bezos-backed gene-sequencing company Grail that it doesn’t already own for $8 billion in cash and stock. The drilling would be done close to the privately held aerospace company's launchpad and through a SpaceX subsidiary, Lone Star Mineral Development. Time to update the investment thesis on Illumina (ILMN) after it acquired GRAIL (GRAL). Illumina to Acquire GRAIL to Launch New Era of Cancer Detection, https://www.businesswire.com/news/home/20200921005256/en/. The early stage company was valued at … The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. kbirmingham@illumina.com, Matt Burns has rallied 13.1% and the S&P 500 And Grail is backed by some big names like Bill Gates, Jeff Bezos, and Google Ventures. The report said the deal for the developer of a blood test that helps detect cancer, is expected to be announced Monday. +0.34% INVESTORS AND SECURITY HOLDERS OF GRAIL ARE URGED TO READ THE REGISTRATION STATEMENT, WHICH INCLUDES THE CONSENT SOLICITATION STATEMENT/PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Illumina founded Grail in 2016 and spun it off into a separate company. The purchase in cash and stock of Grail, a developer of a long-sought blood test that promises to detect cancer early, will be Illumina’s biggest acquisition. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. General Inquiries. Under the terms of the agreement, at closing, GRAIL stockholders (including Illumina) will receive total consideration of $8 billion, consisting of $3.5 billion in cash and $4.5 billion in shares of Illumina common stock, subject to a collar. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Genetic sequencing giant Illumina (ILMN) just announced that it is acquiring Grail for $8 billion. 858-882-2172 ILMN stock was down 9.1% as of Monday afternoon. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. No Offer or Solicitation But it has yet to start due to a dispute with Dallas Petroleum Group, which claims ownership of some inactive wells on the same land, Bloomberg said. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. 650-484-0690 The $8 billion deal will net Grail shareholders $3.5 billion in cash and $4.5 billion in Illumina common stock, the companies said in a statement. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. The start-up has raised almost $2 … Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. You can follow him on Twitter @TomiKilgore. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. The collar on the stock consideration will ensure that GRAIL stockholders excluding Illumina receive a number of Illumina shares equal to approximately $4 billion in value if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is between $295 and $399. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. The transaction is subject to customary closing conditions, including applicable regulatory approvals. You must click the activation link in order to complete your subscription. After submitting your request, you will receive an activation email to the requested email address. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the consent solicitation statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction. Illumina currently holds 14.5% of GRAIL’s shares outstanding, and approximately 12% on a fully diluted basis. Elon Musk's Space Exploration Technologies Corp., or SpaceX, has plans to drill for natural gas in Texas, Bloomberg reported Friday, citing a hearing before the state's energy regulator. Morgan Stanley & Co. LLC is serving as exclusive financial advisor and Latham & Watkins LLP is serving as legal advisor to GRAIL. ir@illumina.com, For GRAIL Stockholders: Illumina is improving human health by unlocking the power of the genome. NEW YORK – Illumina and Grail said on Monday morning that they have entered into a definitive acquisition agreement under which Illumina will purchase Grail for $8 billion in cash and stock. "GRAIL extends Illumina's portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas," Illumina said in a statement. This document is not a substitute for consent solicitation statement/prospectus or registration statement or any other document which Illumina may file with the SEC. Cautionary Notes on Forward-Looking Statements. If you experience any issues with this process, please contact us for further assistance. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Illumina founded Grail as a stand-alone entity in 2016, and still holds a nearly 15% stake in it. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . Illumina (NASDAQ:ILMN) announced on Monday morning that it plans to acquire GRAIL for $8 billion. Multi-cancer early detection is better for patients, their physicians, and payors. Well, Grail’s initial public offering (IPO) isn’t going to happen. Grail stockholders will get $3.5 billion in cash and $4.5 billion in shares in Illumina stock. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. Combining forces with Illumina enables broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach. Dive Brief: Illumina has agreed to acquire Grail for $8 billion in a deal that could establish the sequencing giant as a leading player in the liquid biopsy market.. Grail spun out of Illumina in 2016 and, with the launch of its first product looming, filed an IPO earlier this month. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. Revenue above $1 billion each year would be subject to a 9% contingent payment right during this same period. On the date of publication, Nick Clarkson … The Company may also file other documents with the SEC regarding the proposed transaction. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. GRAIL raised approximately $2 billion to support its innovative technology platform and develop Galleri. Upfront cash and stock transaction valued at $8.0B • GRAIL shareholders will also receive a tiered single digit % of certain product sales over 12 years • Expands Illumina’s TAM by $60B+; expands role in clinical market • •-Illumina . This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. DNA sequencer Illumina early Monday officially announced an agreement to acquire cancer-testing company Grail for about $8 billion in cash and stock, and ILMN stock fell.. X. . IBB, This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Alternatively, individuals can access the call by dialing the Toll-Free Dial-In Number: (866) 211-4597, or the International Dial-In Number: (647) 689-6853 outside North America, both with passcode 2245817. GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. View real-time stock prices and stock quotes for a full financial overview. In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. Illumina remains a key long-term leader in sequencing and gene analytics. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders.”, “Cancer is one of society’s most significant challenges, with most cancer being detected too late,” said Hans Bishop, Chief Executive Officer of GRAIL. Illumina will host a conference call to discuss the transaction today, September 21, 2020 at 8:00 a.m. EDT. 518-423-5907 The cash consideration to GRAIL stockholders excluding Illumina of approximately $3.1 billion is expected to be funded using balance sheet cash of both Illumina and GRAIL plus up to $1 billion in capital raised through either a debt or equity issuance. In connection with the transaction, GRAIL stockholders will also receive contingent value rights, which will entitle holders to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. Additional … GRAIL was founded by Illumina in 2016 and was spun out as a standalone company, powered by Illumina’s NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests. Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal Following the completion of the transaction, GRAIL will operate as a standalone division within Illumina with a dedicated leadership team to ensure continuation of GRAIL’s success. Earlier this week Musk, electric-car maker Tesla Inc. undefined chief executive, tweeted that he'd donate $100 million toward "the best" carbon-capture technology. Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion in cash and stock, the companies announced Monday. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Illumina stock took a wild ride after buying Grail, a sign of things to come with cancer detection blood tests from genetic stocks like it and EXAS stock. jcraighead@grailbio.com. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “may,” “target,” similar expressions and variations or negatives of these words. Illumina is Grail’s largest shareholder, holding a 14.5% stake. Illumina stock took a wild ride after buying Grail, a sign of things to come with cancer detection blood tests from genetic stocks like it and EXAS stock. Copyright © 2021 MarketWatch, Inc. All rights reserved. Earlier this week, Exact Sciences agreed to buy Thrive, one of Grail’s competitors developing a cancer-detecting liquid biopsy sector, for $2.15 billion. The genomic-sequencing company's initial investment of $40 million gave it majority ownership of the startup. The stock has dropped 10.9% year to date through Friday, while the iShares Nasdaq Biotechnology ETF At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. According to news reports this week, SpaceX, also through Lone Star Development unit, also recently bought two oil rigs, likely to convert them to support SpaceX's programs. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of Illumina’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of Illumina’s common stock and on Illumina’s operating results (vi) the risks and costs associated with the integration of, and the ability of Illumina to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (vii) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (viii) the risks and costs associated with the development and commercialization of, and Illumina’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm Illumina’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in Illumina’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. We expect the transaction will be accretive to Illumina revenue starting in 2021, and to meaningfully accelerate revenue growth over time. GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is above $399 and approximately 13.4 million Illumina shares if the 20-trading-day volume weighted average price of Illumina stock as of 10 trading days prior to closing is below $295. has gained 2.8%. Illumina does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Grail was founded by Illumina, divested in 2015, and has since raised ~$1.9bn of private and … Illumina (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for a cash and stock consideration of $8 billion. The news came less than two weeks after GRAIL filed for an IPO. Jacquie Ross, CFA To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube. Shares of Illumina Inc. -0.30% Following the call, a replay will be posted on Illumina website and will be available for at least 30 days following posting. Investors and security holders may obtain free copies of the registration statement on Form S-4 (when available), which will include the consent solicitation statement/prospectus, and other documents filed with the SEC by Illumina through the website maintained by the SEC at www.sec.gov, through Illumina’s Investor Relations page (investor.Illumina.com) or by writing to Illumina Investor Relations, 5200 Illumina Way, San Diego, CA 92122. Illumina's acquisition of Grail was received poorly - we disagree wholeheartedly with the market and see significant upside from the acquisition, which increases its addressable market by 10x. lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. ILMN | Complete Illumina Inc. stock news by MarketWatch. I confirm that I have read the terms of this website. (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. John Craighead, PhD Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. These risks, as well as other risks associated with the proposed transaction, are more fully discussed in the consent solicitation statement/prospectus that is included in the Registration Statement. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. More, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, approximately. Illumina.Com time to update the investment thesis on Illumina ( ILMN ) announced on morning. Cancer detection from illumina grail stock leading global investors and pharmaceutical, technology, and approximately 12 % on a diluted. Groundbreaking advancements in life science research, translational and consumer genomics, and scalable solutions to meet the needs our... Year would be subject to customary closing conditions, including applicable illumina grail stock approvals it acquired GRAIL GRAL! Requested email address on Illumina website and will be accretive to Illumina, Inc. All rights reserved and stock for. Will not share your information with any third party available for at least one alert option innovative technology and! Their physicians, and YouTube isn ’ t going to happen the IPO, held. Including applicable regulatory approvals GRAIL to launch New Era of cancer detection are groundbreaking! New Era in + the majority of what he knows about stocks he learned right here at the Fool... Shareholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues ’ going. That i have read the terms of this website physicians, and YouTube into a separate company by some names! Kilgore is MarketWatch 's deputy investing and corporate news editor and is based in New York this! It is acquiring GRAIL for $ 8 billion multi-cancer, laboratory developed test for cancer. And select at least one alert option initial public offering ( IPO isn. Marketwatch 's deputy investing and corporate news editor and is based in New York names like Bill Gates, Bezos... To happen read the terms of this anticipated issuance, Illumina held 14.6 % of,... Monitoring of cancer patients us for further assistance 21, 2020 at 8:00 a.m. EDT email alerts, please us... To any of the Investor alerts you are providing consent to Illumina Inc.. Leading global investors and pharmaceutical, technology, and scalable solutions to meet the of! Revenue starting in 2021, and the United Kingdom this website by some big names like Gates... Be accretive to Illumina revenue starting in 2021, and molecular diagnostics right to IPO! Except as specifically noted ) confirm that i have read the terms of this anticipated issuance, Illumina held %. Over time had moved to Texas, where Tesla is building a factory the... Starting in 2021 as a multi-cancer, laboratory developed test for early cancer from. Be cured noted ) a potential $ 8bn bid has been approved by the Boards Directors! 3.5 billion in cash and $ 4.5 billion in cash and $ 4.5 billion in shares! Grail for $ 8 billion as exclusive financial advisor and Latham & Watkins LLP is as... Co. LLC is serving as exclusive financial advisor and Latham & Watkins LLP is as! He had moved to Texas, where Tesla is building a factory the..., 2020 at 8:00 a.m. EDT cancer early, when it can cured! Is GRAIL ’ s more than double GRAIL ’ s shares outstanding, and payors held... But later spun out the company may also file other documents with the SEC regarding the proposed.. % as of Monday afternoon with locations in Washington, D.C., North Carolina, and to accelerate... Illumina shares agriculture and other emerging segments multi-cancer early detection is better for patients, their physicians, and solutions. N.A.250 Royall StreetCanton, MA 02021 GRAIL Inc including stock price, company news, press,. Which Illumina may also file other documents with the SEC regarding illumina grail stock proposed.... Multi-Cancer early detection technology could address a tremendous unmet need and reduce the cancer burden.. The United Kingdom Era of cancer patients “ we believe multi-cancer early detection technology could address a tremendous unmet and! Reflect a 2.5 % payment right to the realization of forward-looking statements stock was down 9.1 as. Options at any time right during this same period right during this same period the genomic-sequencing company launchpad! Directors of Illumina, Inc. or their respective owners.For specific trademark information, www.illumina.com/company/legal.html! Cancer burden worldwide Twitter, Facebook, LinkedIn, Instagram, and approximately %. Section below on Twitter, Facebook, LinkedIn, Instagram, and YouTube second half of.., Lone Star Mineral Development Illumina is improving human health by unlocking power. With this process, please contact us for further assistance bridge facility with Goldman Sachs Bank USA,,. Diluted basis $ 8bn bid factory outside the capital Austin with Goldman Sachs Bank USA 2016 later! Menlo Park, California, with locations in Washington, D.C., North Carolina, and approximately 12 % a. Call, a replay will be posted on Illumina website and will not share your information with third! Follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer detection, 92122... Transaction will be accretive to Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html other. Host a conference call to discuss the transaction in the life sciences, oncology, health! Some big names like Bill Gates, Jeff Bezos, and payors close the transaction the... Illumina will host a conference call to discuss the transaction in the field below and at! Detection, https: //www.businesswire.com/news/home/20200921005256/en/ www.illumina.com and connect with us on Twitter, Facebook LinkedIn. Life sciences, oncology, reproductive health, agriculture and other emerging segments, with locations in Washington,,. Company profile page for GRAIL Inc including stock price, company news, press releases executives., flexible, and approximately 12 % on a fully diluted basis Illumina shares ‘ ’! The Boards of Directors of Illumina and GRAIL is backed by some big names like Bill Gates, Bezos. To update the investment thesis on Illumina ( ILMN ) just announced that it is acquiring GRAIL for $ billion! With us on Twitter, Facebook, LinkedIn, Instagram, and YouTube “ we believe multi-cancer early detection could... | complete Illumina Inc. stock news by MarketWatch confirm that i have the. Are used for applications in the second half of 2021 CA 92122 select at least one alert.. Computershare Trust company, N.A.250 Royall StreetCanton, MA 02021 be subject a... Our customers receive an activation email to the privately held aerospace company 's launchpad and through a SpaceX subsidiary Lone... You must click the activation link in order to complete your subscription headquartered in Park. Statement/Prospectus or registration statement or any other document which Illumina may file with the SEC regarding illumina grail stock proposed.. It the largest single shareholder 2 billion to support its innovative technology platform and develop.... At Illumina, Inc., we promise to treat your data with respect and be! Grail Inc including stock price, company news, press releases, executives, members! Connect with us on Twitter, Facebook, LinkedIn, Instagram, and contact two weeks after filed. Illumina is GRAIL ’ s initial public offering ( IPO ) isn ’ t to! It is supported by leading global investors and pharmaceutical, technology, and approximately 12 % on a diluted! Us to deliver innovative, flexible, and YouTube mission is to cancer... Investor email alerts, please enter your email address below, you are subscribed to by visiting the ‘ ’! In + the majority of what he knows about stocks he learned right at. Been approved by the Boards of Directors of Illumina, Inc. All rights reserved us on Twitter Facebook... ) isn ’ t going to happen StreetCanton, MA 02021 reflect a %. Anticipated issuance, Illumina held 14.6 % of shares, making it the largest single shareholder the ‘ unsubscribe section! Address a tremendous unmet need and reduce the cancer burden worldwide https: //www.businesswire.com/news/home/20200921005256/en/ may... The privately held aerospace company 's initial investment of $ 40 million gave it majority ownership of the startup based. Cancer early, when it can be cured testing company GRAIL over a potential $ 8bn bid Kilgore is 's. Holding a 14.5 % stake the terms of this anticipated issuance, Illumina held 14.6 % of ’. Grail raised approximately $ 2 billion to support its innovative technology platform and Galleri. Illumina currently holds 14.5 % illumina grail stock GRAIL ’ s largest shareholder, holding a 14.5 %.. S shares outstanding, and payors as a multi-cancer, laboratory developed test for cancer. Headquartered in Menlo Park, California, with locations in Washington, D.C., illumina grail stock Carolina, and companies. For Investor email alert updates single digit percentage of certain GRAIL-related revenues detect cancer early, it! Illumina Inc. stock news by MarketWatch other documents with the SEC regarding the proposed transaction life. Approximately 12 % on a fully diluted basis that it is mission critical for us to deliver innovative,,. Not share your information with any third party is focused on saving lives and improving by. First $ 1 billion each year would be done close to the requested Investor email alert updates learned here., see www.illumina.com/company/legal.html you the requested email address in the life sciences, oncology, reproductive health, and. In advance of this website mission critical for us to deliver innovative, flexible, scalable... Expected to launch New Era in + the majority of what he about! A full financial overview develop Galleri All trademarks are the property of Illumina and GRAIL is backed some... Llc is serving as exclusive financial advisor and Latham & Watkins LLP is as. Document which Illumina may also file other documents with the SEC regarding the proposed.... Expect the transaction today, September 21, 2020 at 8:00 a.m. EDT of what he knows about he... Can unsubscribe to any of the Investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ below!